“You have been saving money for my studies, haven't you? I would like you to donate that money to the Máxima Center, to help other children with brain cancer as well.”

- Veerle, January 28, 2022, shortly after her diagnosis


In early 2022, Veerle (12) was diagnosed with a Diffuse Midline Glioma (DMG), a rare and aggressive form of brain cancer, with a very low survival rate so far.

Veerle, cheerful, positive, and resilient as she is, did not let the diagnosis get her down. Together with family and friends she launched the Veer(le)kracht initiative (The word 'veerkracht' means resilient in Dutch). Her aim with this initiative is to raise funds for much-needed and innovative research into childhood DMGs in the Netherlands, in order to offer children who suffer from DMGs, such as Veerle, a better chance of survival.

Several promising medical trials in the field of DMGs have already been started outside of Europe. Doctors at the Princess Máxima Center (a specialized children’s oncology hospital in Utrecht, The Netherlands) now want to bring these trials to the Netherlands. The start-up costs of the first trial with the drug ONC201, which should start in the fall of this year, amount to € 200.000. Raising this amount was the first concrete goal of the Veer(le)kracht Foundation. We achieved this goal in only a very short time! For this we are obviously very grateful and indebted to all the generous donors and the many great fundraising campaigns that have been initiated since our foundation was launched. It would be great if Veerle could also participate in this first trial.

While this initial success is wonderful, our mission is far from over. Only with more research there can be hope for a better future for children with a DMG. But all that research requires a lot more money that unfortunately cannot be financed from existing healthcare budgets. Therefore, The Veer(le)kracht Foundation remains committed to (co-)funding more research into childhood DMGs. Support our mission!


Logo_Veerlekracht-01 (1)